Clinical trial
Avastin and Taxotere for Esophagogastric Cancer
NCT00137813 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00137813 |
|---|---|
| Title | Avastin and Taxotere for Esophagogastric Cancer |
| Official title | Phase II Study of Bevacizumab and Docetaxel (AvaTax) in Metastatic Esophagogastric Cancer |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Brigham and Women's Hospital Massachusetts General Hospital Beth Israel Deaconess Medical Center Genentech, Inc. Industry Sanofi |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Esophageal Cancer, Gastric Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel, Bevacizumab |
| Enrollment | 42 |
| Start date | Aug 1, 2004 |
| Primary completion | Sep 1, 2006 |
| Completion | Sep 1, 2009 |
| First posted | Aug 30, 2005 |
| Last update posted | Nov 1, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: